Meet the Professor

Dr. Ghassan K. Abou-Alfa: iMDT is a precious and great channel for building relationships to learn from each other

Received: 25 July 2018; Accepted: 31 July 2018; Published: 24 August 2018.
doi: 10.21037/amj.2018.08.01
View this article at: http://dx.doi.org/10.21037/amj.2018.08.01

Expert’s introduction

Dr. Ghassan Abou-Alfa (Figure 1) specializes in hepatocellular cancer as a member of Memorial Sloan Kettering. He received his MD degree in American University of Beirut and served on the faculty of the Department of Medicine in Yale University School of Medicine before he joined Memorial Sloan Kettering Cancer Center and Joan & Sanford I, Weill Medical Scholl at Cornell University in 2001. Dr. Abou-Alfa also received his MBA from Columbia University in 2016.

Dr. Abou-Alfa’s research is dedicated to finding novel therapies and improving the effectiveness current therapies for hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer, while continuing to understand the basic mechanisms of the disease and its therapies. Dr. Abou-Alfa has many publications in the field of hepatocellular carcinoma. He led on many occasions, international teams of investigators, and published the first report on the effective role of the novel agent sorafenib in the treatment of primary liver cancer and recently reported with colleagues from throughout the world, the positive outcome of the study he chaired on cabozantinib in the treatment of hepatocellular carcinoma in the New England Journal of Medicine. Dr. Abou-Alfa serves as the Chair of the National Cancer Institute (NCI) Task Force for Hepatobiliary Cancers, and is the President-Elect for the International Society of Gastrointestinal Oncology. Dr. Abou-Alfa chairs the hepatocellular carcinoma subgroup of the Alliance cooperative group, and is a cadre member of both the gastrointestinal cancers and pharmacogenomics and population pharmacology committees. Dr. Abou-Alfa serves as the chair the medical/scientific board of the Cholangiocarcinoma Foundation and the Blue Faery Liver Foundation, and also serves on the National Medical Advisory Committee of the American Liver Foundation. Dr. Abou-Alfa who has lectured worldwide on the subject on gastrointestinal malignancies, is also a strong advocate for raising awareness and support for improving the outcome of patients with these diseases, and enhancing oncologic education worldwide.

Editor’s note

The multidisciplinary team (MDT) discussion has earned increasing popularity for the complex needs asking for the coordination of health and social care. In response to this complexity, relational coordination, the concept of International Multidisciplinary Team (iMDT) is put forwarded.

We had the great honor to invite Dr. Ghassan K. Abou-Alfa from Memorial Sloan Kettering Cancer Center, to have an interview with us on his experience and thoughts of clinical and academic importance of iMDT.
An elderly man with remote history of metastatic melanoma now with localized pancreatic cancer and new liver masses

Neil Vassö, Marta Igozhe Bregaržič, Alexander N. Shoushtari,1,1 Richard Kish Gian Do,1,2,3 Marcelo Eibl-Braunstein,1,4 Ali Shoshendeib,5 Widad Tariq,6 Deborah Mokrič,5 Ali Haddar,7 Ashwag Omerz,8 Frank Sabotič,9 Rita Assz,10 Imre El Dika,11 Leonard B. Salz11,2,3,6,7,8,9,10,11,12,13,14,15

1National Sloan-Kettering Cancer Center, New York, NY, USA, Division of Oncology, Institute of Cancer of Sj Pauls, University of Sj Pauls, Sj Pauls, Brazil; 2Noél Counsel Medical, New York, NY, USA; 3Austria Venom Center of Bonn, Bonn, Germany; 4National Cancer Hospital, Budapest, Hungary; 5Saad, Kingdom of Saudi Arabia; 6Communications by Ghassan K. Abou-Alfa, Memorial Sloan-Kettering Cancer Center, NY; Email: amj.amegroups.com

Introduction

Since 2015, Dr. Ghassan K. Abou-Alfa has launched a special column Educational Case Series of the Memorial Sloan-Kettering Cancer Center in the Journal of Gastrointestinal Oncology (JGO) (Figure 2). This case series is published in the form of dialogue, which presents a lively MDT discussion. “More than ten years ago, we have launched and established few regular conferences with other institutions to present and discuss specific medical cases to learn from. Experts from Memorial Sloan-Kettering Cancer Center attend the conferences to discuss and comment on the selected cases, with the purpose of educating our fellows as well as fellows and junior faculty from other institutions. These very successful conferences had also led and helped establishing and developing new relationships among the faculty from the different institutions,” Dr. Abou-Alfa, “We discovered in no time that publishing the cases and discussions has good educational and learning value. The launch of Educational Case Series of the Memorial Sloan-Kettering Cancer Center in the Journal of Gastrointestinal Oncology (JGO) is a significant effort we are all proud of. The publication of this case series in JGO helped further the connectivity and access among our colleagues at Memorial Sloan Kettering and the institutions in China. This helped share with the world how we treat patients. This opportunity is a very precious and great channel for building relationships.”

Before launching the Educational Case Series of Memorial Sloan–Kettering Cancer Center in JGO, we published case reports in other journals, e.g., Gastrointestinal Cancer Research (GCR) Dr. Abou-Alfa, “we have already published more than close to thirty cases.”

Why Dr. Abou-Alfa strives for this?

“The vision of our Physician-In-Chief Dr. José Baselga, to help expand our understanding and care for cancer patients globally, reflect on the opportunity to discuss complex cases and provide guidance and sometimes help care for those patients. This adds to the tremendous opportunity this provides for the young faculty and fellow to learn how to start writing their own manuscripts and benefit from this hands-on experience in writing. This will also ensure that our colleagues and us remain connected through the regular conferences, and help enhance further interaction and cooperation opportunities among our institutions, e.g., visiting faculty, workshops, and meetings.” Dr. Abou-Alfa said.

“This also has taught us that perspectives and care methodologies may differ. We share with the world how we treat patients at Memorial Sloan Kettering, but also learn how things are done in China or other parts of the world. Case reports and case consultation are a great opportunity to learn from each other. We do appreciate that things can be handled differently and appreciate what we can learn from each other.”

EDUCATIONAL CASE SERIES OF THE MEMORIAL SLOAN–KETTERING CANCER CENTER

Interview

Since 2015, Dr. Ghassan K. Abou-Alfa has launched a special column Educational Case Series of the Memorial Sloan–Kettering Cancer Center in the Journal of Gastrointestinal Oncology (http://jgo.amegroups.com/index).

Figure 2 Educational Case Series of the Memorial Sloan-Kettering Cancer Center in the Journal of Gastrointestinal Oncology (http://jgo.amegroups.com/index).

Dr. Vassö: This is the case of an 84-year-old man who presented to his primary care physician with abdominal discomfort and diarrhea. Esophagogastroduodenoscopy (EGD) was unremarkable. Computed tomography (CT) of the abdomen and pelvic magnetic resonance cholangiopancreatography (MRCP) were obtained. Serum tumor markers were not available.

Dr. Do: On the coronal image (Figure 1-6) we see bile duct dilatation that is interrupted at the level of the pancreatic head, and on the main image (Figure 1-B) a relatively normal appearing pancreatic head. On MRCP (Figure 2-C) you can see a double duct sign which is a dilated pancreatic duct and dilated bile duct. The double duct sign is almost pathognomonic for malignancy in pancreatic head and ampullary (1). The absence of a discrete radiographic mass may be a good prognostic sign given that the mass may be small enough for cure. This can lead to endoscopic ultrasound or even directly to surgery.

Dr. Omerz: Dr. Do, could you please comment on the lymph nodes and the resection?

Dr. Vassö: No lymphadenectomy is noted. On the axial view (Figure 1-B) there is a complete flat plate between the superior mesenteric vein (SMV) and the posterior pancreatic head mass. There is also no involvement of the inferior vena cava or the superior mesenteric artery (SMA).

Dr. Vassö: The patient underwent endoscopic ultrasound and fine needle aspiration which demonstrated an ampullary with a focal smooth deformity and mass consistent with an intraepithelial neoplastic lesion (INPL). Fine needle aspiration fluid showed CEA of 190 ng/ml, and amylase greater than 183,300 units/L. Cytology showed suspicious cells, likely INPL.

Dr. Vassö: The patient’s past medical history was significant for remote metastatic melanoma. Twenty-six years before, he developed a chest wall lesion and underwent resection. Pathology showed melanoma. He underwent bilateral prophylactic mastectomy which demonstrated lymph nodes positive for melanoma. He received an adjuvant therapy. Four months later, he had surveillance scans which showed metastatic liver lesions. It was not clear if he had a liver biopsy. He was treated with dacarbazine, etoposide, carboplatin, and interferons based on the Dartmouth protocol (2). He had a complete response. He was continued on maintenance dacarbazine and then on felty’s for five years and had no evidence of disease. Thereafter he was monitored expectantly. His other history was significant for arterial dilatation, superior mesenteric artery thrombus, and gastroparesis reflux disease. He had a prior cholecystectomy for cholecystitis. He is a non-smoker. He is of Ashkenazi-Jewish ethnic origin.

Dr. Omerz: Dr. Vassö, thanks for joining us. Could you comment on his neuroendocrine management?

Dr. Vassö: The Dartmouth protocol is continuing systemic regimen developed at Dartmouth University in the 1980s (2). As many chronic regimen is needed. It is associated with a 10-15% response rate. A phase III

© AME Medical Journal, 2018. All rights reserved.

References

1. National Sloan-Kettering Cancer Center, New York, NY, USA; Division of Oncology, Institute of Cancer of Sj Pauls, University of Sj Pauls, Sj Pauls, Brazil; Noél Counsel Medical, New York, NY, USA; Austria Venom Center of Bonn, Bonn, Germany; National Cancer Hospital, Budapest, Hungary; Saad, Kingdom of Saudi Arabia; Communications by Ghassan K. Abou-Alfa, Memorial Sloan-Kettering Cancer Center, NY; Email: amj.amegroups.com

View this article: https://doi.org/10.21037/amj.2018.01.21

© Journal of Gastrointestinal Oncology. All rights reserved.

Figure 2 Educational Case Series of the Memorial Sloan-Kettering Cancer Center in the Journal of Gastrointestinal Oncology (http://jgo.amegroups.com/index).

iMDT corner

A MDT approach is considered best practice in the treatment planning and care for patients, specially for patients with cancer. At the end of 2016, a conversation between Mr. Stephen Wang, the founder of AME Publishing Company and Dr. Jianfei Shen, the Physician of Taizhou Hospital of Zhejiang Province, Wenzhou Medical University was a starting point of a new program, iMDT. It is an updated version of MDT. All the discussion with experts worldwide ultimately will be expanded into a manuscript published in one of journals under AME. So
Multidisciplinary team approach on a case of bilateral tension pneumothorax

Xiaodong Li1, Xiaofen Su2, Baolei Chen3, Haijun Yao4, Yuehan Yu5, Xuefeng Leng6, Qiang Lu6, Chongying Wang7, Jiangmao Liu7, Kun Ruan8, Fazlurahman Kazi9, Schausubh Bhabha10, Young Chitt11, Pier Luigi Filippo12, Jiaofei Shen13, Chengchu Zhu13; Written on behalf of AME Thoracic Surgeons Collaborative Group

1Department of Cardiothoracic Surgery, Zhongshan Hospital of Fudan University, Shanghai Medical University, Shanghai, China; 2Department of Respiratory Medicine, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; 3School of Medicine, Shandong University, Jinan, China; 4Thoracic Care Unit, the South People’s Hospital of Shanghai Jiao Tong University, Shanghai, China; 5Thoracic Care Unit, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; 6Department of Thoracic Surgery, the Affiliated Hospital of Chongqing University, Chongqing, China; 7Department of Thoracic Surgery, Tangzi Hospital, the Fourth Military Medical University, Xi’an, China; 8Department of Thoracic Surgery, the Affiliated Hospital of Chongqing University, Chongqing, China; 9Department of Thoracic Surgery, the Affiliated Hospital of Tongji University, Shanghai, China; 10Department of Thoracic Surgery, the Affiliated Hospital of Fudan University, Shanghai, China; 11Department of Thoracic Surgery, Tianjin Medical University, Tianjin, China; 12Department of Thoracic Surgery, the Fourth Military Medical University, Xi’an, China; 13Division of Thoracic Surgery, Department of Thoracic Surgery, University of Ottawa, Ottawa, Canada.

© AME Medical Journal. All rights reserved. AME Med J 2018;3:88 amj.amegroups.com

© AME Medical Journal. All rights reserved. AME Med J 2018;3:88 amj.amegroups.com

Figure 3 iMDT corner in Journal of Thoracic Disease (http://jtd.amegroups.com/article/view/20854/html).

doi: 10.21037/amj.2018.08.01

Cite this article as: Li G, Zhou S. Dr. Ghassan K. Abou-Alfa: iMDT is a precious and great channel for building relationships to learn from each other. AME Med J 2018;3:88.

media in China. All the contents could be accessible to more Chinese doctors as well.

What is the clinical and academic importance of the iMDT platform respectively?

Dr. Abou-Alfa, “It is a great opportunity to build and promote relationships, enhance potential cooperation for academic work, research, and patient care. This may also help develop workshops, courses, and conferences collaboratively.”

“No doubt that the International Multidisciplinary Consultation has a tremendous and important value. Physicians being in the US, China or anywhere else, of course are very pound and would speak up how they like to do things. It is very important for us to learn from each other to better understand how things are done. There are many other channels for us to keep track of the latest developments of medicine in China, and iMDT is one of them. It is a great warmup for other potential opportunities. This is a great potential for further collaboration among physicians for patients, and learn from each other through collaborative conferences, courses, workshops.”

Acknowledgements

We would like to extend our gratitude to Dr. Ghassan Abou-Alfa for sharing his experience and thoughts with us.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

(Science Editors: Grace Li, Silvia Zhou, AMJ, amj@amegroups.com)